HAART induced inflammation, toxicity and its determinants among HIV positive children in Addis Ababa, Ethiopia.
Hematologic toxicity
Inflammation
Liver toxicity
Renal toxicity
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
10
10
2022
revised:
18
04
2023
accepted:
21
04
2023
medline:
22
5
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
epublish
Résumé
Highly Active Antiretroviral therapy (HAART) plays significant role in reduction of mortality among children infected with HIV. Despite the inevitable impact of HAART on inflammation and toxicity, there is limited evidence on its impact among children in Ethiopia. Moreover, evidence on contributing factors to toxicity has been poorly described. Hence, we evaluated HAART induced inflammation and toxicity among children taking HAART in Ethiopia. This cross-sectional study was conducted among children (<15 years old) taking HAART in Ethiopia. Stored plasma samples and secondary data from a previous study on HIV-1 treatment failure were used for this analysis. By 2018, a total of 554 children were recruited from randomly selected 43 health facilities in Ethiopia. The different levels of liver (SGPT), renal (Creatinine) and hematologic toxicity (Hemoglobin) toxicity were assessed using established cut-off value. Inflammatory biomarkers (CRP and vitamin-D) were also determined. Laboratory tests were done at the national clinical chemistry laboratory. Clinical and baseline laboratory data were retrieved from the participant's medical record. Questionnaire was also administered to study guardians to assess individual factors to inflammation and toxicity. Descriptive statistics was used to summarize the characteristics of the study participants. Multivariable analysis was conducted and considered significant at P < 0.05. Overall 363 (65.6%) and 199 (36%) of children taking HAART in Ethiopia developed some level of inflammation and vitamin-D in-sufficiency, respectively. A quarter of the children 140 (25.3%) were at Grade-4 liver toxicity while renal toxicity were 16 (2.9%). A third 275 (29.6%) of the children also developed anemia. Children who were on TDF+3 TC + EFV, those who were not virally suppressed and children with liver toxicity were at 17.84 (95%CI = 16.98, 18.82), 2.2 (95%CI = 1.67, 2.88) and 1.20 (95%CI = 1.14, 1.93) times risk of inflammation, respectively. Children on TDF+3 TC + EFV, those with CD4 count of <200 cells/mm The high level of HAART induced inflammation and liver toxicity among children calls for the program to consider safer regimens for pediatric patients. Moreover, the high proportion of vitamin-D in-sufficiency requires program level supplement. The impact of TDF+3 TC + EFV on inflammation and vitamin-D deficiency calls for the program to revise this regimen.
Sections du résumé
Background
UNASSIGNED
Highly Active Antiretroviral therapy (HAART) plays significant role in reduction of mortality among children infected with HIV. Despite the inevitable impact of HAART on inflammation and toxicity, there is limited evidence on its impact among children in Ethiopia. Moreover, evidence on contributing factors to toxicity has been poorly described. Hence, we evaluated HAART induced inflammation and toxicity among children taking HAART in Ethiopia.
Method
UNASSIGNED
This cross-sectional study was conducted among children (<15 years old) taking HAART in Ethiopia. Stored plasma samples and secondary data from a previous study on HIV-1 treatment failure were used for this analysis. By 2018, a total of 554 children were recruited from randomly selected 43 health facilities in Ethiopia. The different levels of liver (SGPT), renal (Creatinine) and hematologic toxicity (Hemoglobin) toxicity were assessed using established cut-off value. Inflammatory biomarkers (CRP and vitamin-D) were also determined. Laboratory tests were done at the national clinical chemistry laboratory. Clinical and baseline laboratory data were retrieved from the participant's medical record. Questionnaire was also administered to study guardians to assess individual factors to inflammation and toxicity. Descriptive statistics was used to summarize the characteristics of the study participants. Multivariable analysis was conducted and considered significant at P < 0.05.
Result
UNASSIGNED
Overall 363 (65.6%) and 199 (36%) of children taking HAART in Ethiopia developed some level of inflammation and vitamin-D in-sufficiency, respectively. A quarter of the children 140 (25.3%) were at Grade-4 liver toxicity while renal toxicity were 16 (2.9%). A third 275 (29.6%) of the children also developed anemia. Children who were on TDF+3 TC + EFV, those who were not virally suppressed and children with liver toxicity were at 17.84 (95%CI = 16.98, 18.82), 2.2 (95%CI = 1.67, 2.88) and 1.20 (95%CI = 1.14, 1.93) times risk of inflammation, respectively. Children on TDF+3 TC + EFV, those with CD4 count of <200 cells/mm
Conclusion
UNASSIGNED
The high level of HAART induced inflammation and liver toxicity among children calls for the program to consider safer regimens for pediatric patients. Moreover, the high proportion of vitamin-D in-sufficiency requires program level supplement. The impact of TDF+3 TC + EFV on inflammation and vitamin-D deficiency calls for the program to revise this regimen.
Identifiants
pubmed: 37215860
doi: 10.1016/j.heliyon.2023.e15779
pii: S2405-8440(23)02986-9
pmc: PMC10195915
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e15779Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Semin Liver Dis. 2012 May;32(2):167-76
pubmed: 22760656
J Med Toxicol. 2014 Mar;10(1):26-39
pubmed: 23963694
Nanotheranostics. 2022 Aug 21;6(4):436-450
pubmed: 36051856
S Afr Med J. 2005 Apr;95(4):253-7
pubmed: 15889848
AIDS Res Ther. 2007 May 14;4:11
pubmed: 17502001
Arch Intern Med. 2006 Jan 9;166(1):64-70
pubmed: 16401812
AIDS Res Hum Retroviruses. 2008 Nov;24(11):1375-82
pubmed: 18928396
Pediatric Health Med Ther. 2017 May 10;8:47-55
pubmed: 29388633
Biomed Res Int. 2015;2015:735615
pubmed: 26000302
J Infect Dis. 2011 Jun 1;203(11):1637-46
pubmed: 21592994
BMC Res Notes. 2016 Nov 2;9(1):483
pubmed: 27806729
PLoS One. 2019 Sep 6;14(9):e0221653
pubmed: 31490959
HIV AIDS (Auckl). 2016 Dec 22;9:1-7
pubmed: 28053556
Kidney Int. 2018 Mar;93(3):545-559
pubmed: 29398134
Nutrients. 2015 Nov 10;7(11):9218-28
pubmed: 26569292
Sex Transm Infect. 2001 Jun;77(3):158-73
pubmed: 11402222
AIDS Res Hum Retroviruses. 2009 Sep;25(9):861-7
pubmed: 19689190
Clin Infect Dis. 2014 Nov 1;59(9):e96-138
pubmed: 25234519
BMC Endocr Disord. 2019 Jul 22;19(1):77
pubmed: 31331321
Lancet. 2013 Apr 20;381(9875):1391-1403
pubmed: 23473847
J Infect Dis. 2015 Oct 1;212(7):1100-10
pubmed: 25762788
PLoS One. 2012;7(7):e40180
pubmed: 22808112
Indian J Sex Transm Dis AIDS. 2016 Jul-Dec;37(2):123-128
pubmed: 27890944
BMC Res Notes. 2019 Oct 30;12(1):714
pubmed: 31666123
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):290-6
pubmed: 21602695
HIV AIDS (Auckl). 2020 Mar 17;12:107-112
pubmed: 32231441
AIDS Res Treat. 2016;2016:1985452
pubmed: 27493798
Lancet. 2000 Oct 21;356(9239):1423-30
pubmed: 11052597
Presse Med. 2005 Nov 19;34(20 Pt 2):1571-8
pubmed: 16314816
J Antimicrob Chemother. 2005 Aug;56(2):380-7
pubmed: 15996972
BMC Infect Dis. 2012 Nov 15;12:304
pubmed: 23151221
Immunol Rev. 2013 Jul;254(1):114-42
pubmed: 23772618